Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab versus placebo in impaired glucose tolerance or type 2 diabetes
2009-016604-23Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prediabetes and type 2 diabetes mellitus (T2DM) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Change from baseline in meal challenge-derived insulin secretion rate relative to glucose 0-2 hours. Started Nov 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016604-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016604-23.